Huilin

About Huilin

Quantitative Systems Pharmacologist specializing in QSP, PBPK, and PK/PD modeling to drive data-informed drug development decisions across immunology, oncology, and CNS programs.As Associate Director at Bristol Myers Squibb, I drive translational modeling strategies that integrate preclinical, biomarker, and clinical data to inform dose selection, exposure–response analysis, and trial design.My work has contributed directly to IND submissions, FDA briefing documents, and global regulatory interactions, supporting phase 1–3 development decisions. I specialize in bridging mechanistic disease modeling with clinical pharmacology to optimize dosing regimens, characterize variability, and strengthen regulatory narratives.With a background spanning academia and industry, including postdoctoral research in immuno-oncology modeling at Johns Hopkins, I bring a strong foundation in mechanistic modeling while maintaining a clear focus on both preclinical and clinical impact and decision support.I am particularly interested in advancing model-informed precision dosing, reverse translation, and integrated clinical pharmacology strategies that enhance development efficiency and improve patient outcomes.Core expertise includes:• Quantitative Systems Pharmacology (QSP)• PBPK and PK/PD modeling• Translational disease modeling and reverse translation• Regulatory strategy support• Mechanistic immunology, oncology and CNS modeling

Experience

1. Bristol Myers Squibb

   Present

Education

• China Pharmaceutical University

  Bachelor of Science (BS), Bioengineering

  2009 — 2013

• Syracuse University

  Master of Science (MS), Biomedical Engineering

  2013 — 2015

• Syracuse University

  Doctor of Philosophy - PhD, Biomedical Engineering

  2015 — 2019